OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Financial and business highlights Total H1 2024 incomes of €82.5 million thanks to Company’s new partnerships.New strategic partnership with AbbVie for up to $713 million, including $48 million received upon signature.Major partnership expansion with Boehringer Ingelheim: Amendment of the collaboration and licensing agreement on […]
The post OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update first appeared on San Francisco News.
—-
Author : SanFrancisco
Publish date : 2024-09-27 03:07:45
Copyright for syndicated content belongs to the linked Source.